FPE3:XETRFUCHS SE Pref Registered Shs Analysis
Data as of 2026-03-14 - not real-time
€33.92
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Fuchs SE is trading at €33.92, comfortably below its 20‑day SMA of €36.14 and the 50‑day SMA of €37.37, signaling a short‑term bearish bias. Technical indicators reinforce this view: the RSI sits at 29, suggesting oversold conditions, while the MACD line remains negative and the histogram is shrinking, confirming bearish momentum. Yet the stock is perched just above a solid support level of €33.82 and volume is on the rise, hinting at a possible bottom‑testing bounce. Fundamentally, the company delivers a robust dividend yield of 3.45% with a payout ratio near 52%, supported by free cash flow of €284 million and a healthy ROE of 15.9%. The DCF‑derived fair value of €32.79 places the current price only modestly above intrinsic value, while analyst consensus (10 analysts, strong‑buy) targets a median price of €49.5, implying significant upside. Risk factors include elevated 30‑day volatility (~21%) and a max drawdown of over 30%, though the low beta (~0.30) tempers market‑wide exposure.
Given the blend of a potentially oversold technical setup, attractive dividend profile, and strong long‑term fundamentals, the stock appears undervalued relative to its growth prospects. The bearish short‑term trend may be short‑lived, offering a window for opportunistic buying, while the medium‑to‑long‑term outlook remains positive as the company leverages its global specialty‑chemical footprint. The overall risk is moderate, with sector cyclicality and regulatory scrutiny balanced by solid cash generation and low market correlation.
Given the blend of a potentially oversold technical setup, attractive dividend profile, and strong long‑term fundamentals, the stock appears undervalued relative to its growth prospects. The bearish short‑term trend may be short‑lived, offering a window for opportunistic buying, while the medium‑to‑long‑term outlook remains positive as the company leverages its global specialty‑chemical footprint. The overall risk is moderate, with sector cyclicality and regulatory scrutiny balanced by solid cash generation and low market correlation.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- RSI indicates oversold conditions
- Price near strong support at €33.82
- Increasing volume suggests potential bounce
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Analyst consensus strong‑buy with median target €49.5
- Attractive dividend yield and sustainable payout
- Fair valuation relative to DCF and solid cash flow
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Low beta provides defensive characteristics
- Global diversification across automotive and industrial markets
- Consistent profitability and strong ROE
Key Metrics & Analysis
Financial Health
Revenue Growth-0.70%
Profit Margin8.29%
P/E Ratio15.1
ROE15.97%
ROA10.17%
Debt/Equity5.91
P/B Ratio2.4
Op. Cash Flow€382.0M
Free Cash Flow€284.4M
Technical Analysis
TrendBearish
RSI29.1
Support€33.82
Resistance€37.52
MA 20€36.14
MA 50€37.37
MA 200€40.30
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88
Valuation
Fair Value€32.79
Target Price€48.90
Upside/Downside44.16%
GradeFair
TypeValue
Dividend Yield3.45%
Risk Assessment
Beta0.30
Volatility21.48%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.